Filing Details
- Accession Number:
- 0001181431-14-004413
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-01-30 16:42:29
- Reporting Period:
- 2014-01-29
- Filing Date:
- 2014-01-30
- Accepted Time:
- 2014-01-30 16:42:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1325879 | Aveo Pharmaceuticals Inc | AVEO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1486359 | Jeno Gyuris | C/O Aveo Pharmaceuticals, Inc. 650 E. Kendall Street Cambridge MA 02142 | Svp, Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2014-01-29 | 3,200 | $0.00 | 99,245 | No | 4 | D | Direct | |
| Common Stock | Disposition | 2014-01-30 | 5,430 | $1.64 | 93,815 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | D | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right-to-buy) | Acquisiton | 2014-01-29 | 75,000 | $0.00 | 75,000 | $1.77 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 75,000 | 2024-01-29 | No | 4 | A | Direct |
Footnotes
- Shares underlying such disposition to the issuer were forfeited by the reporting person pursuant to the terms of an award of restricted stock granted to the reporting person on June 26, 2013 in connection with the determination of the issuer's Compensation Committee that certain specified strategic performance objectives were not met.
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2013, which was implemented to cover taxable events related to the partial vesting of certain restricted stock.
- The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.61 to $1.69, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- This option vests in equal monthly installments from January 1, 2014 through January 1, 2018.
Billionaire Hedge Funds
